BioPorto

Environmental & Social Information • Feb 13, 2016

An article by BioPortos European Advisory Board chaired by Prof. Dr. Jean-Louis
Vincent on the suggested use of NGAL in clinical practice, specifically in
cardiac surgical procedures, has been accepted into the prestigious American
journal The Journal of Thoracic and Cardiovascular Surgery.

While a large number of scientific articles documenting NGAL’s use as a marker
for the detection of acute kidney injury have been published, the Advisory
Board’s white paper is the first article to be based on reported clinical use
of the test and suggesting guidelines for the intervention and patient
management both before and after the operation based on measurements of NGAL.

For the first time, the article equips the clinical staff at the cardiac
intensive care unit with a decision algorithm for the practical application of
NGAL. BioPorto expects that the article will be given weight in the
decision-making processes that lead to the inclusion of NGAL tests in official
clinical guidelines, which in several countries are determined at a national
level.

Peter Mørch Eriksen, CEO of BioPorto, said: "The Journal of Thoracic and
Cardiovascular Surgery publishing the Advisory Board’s white paper is an
important recognition of NGAL and a strategic milestone for BioPorto. I am
convinced that the article with the suggested guidelines will open doors for
NGAL-based tests worldwide and contribute to faster and improved renal injury
diagnostics for the benefit of patients and clinicians."

For further information, please contact:

Peter Mørch Eriksen, CEO

Christina Thomsen, Investor Relations Manager

Telephone +45 4529 0000, e-mail investor@bioporto.com

The kidney biomarker NGAL

Every year about 13 million people are struck by acute kidney injury worldwide,
of whom about 4 million die. Nevertheless, there has been no real progress in
methods of diagnosing kidney injury over the last half century. Existing
methods, such as serum creatinine determination, only signal kidney failure
24-72 hours after the injury has taken place. In contrast, NGAL rises to
diagnostic levels within a few hours of kidney injury and thus enables the
physician to make vital clinical decisions before the damage progresses to
potentially fatal renal shutdown. In addition to helping the patient,
cost-benefit analyses show that implementing NGAL testing will contribute to
reducing hospital costs in the management of kidney injury and its
consequences.

About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides
healthcare professionals in clinical and research settings a range of
diagnostic tests and antibodies. Our pioneering product portfolio includes
assays for underserved disease states such as NGAL for acute kidney injury. We
sell our products in more than 80 countries through diverse sales channels and
partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on
the NASDAQ Copenhagen stock exchange.